» Articles » PMID: 35412941

Circular RNA Circ_0004277 Inhibits Acute Myeloid Leukemia Progression Through MicroRNA-134-5p / Single Stranded DNA Binding Protein 2

Overview
Journal Bioengineered
Date 2022 Apr 12
PMID 35412941
Authors
Affiliations
Soon will be listed here.
Abstract

Circular RNAs (circRNAs) are crucial non-coding RNAs in the process of tumorigenesis. Nevertheless, the biological function of circ_0004277 in acute myeloid leukemia (AML) is blurred. Microarray data of circRNAs were utilized to evaluate circRNAs' differential expression in AML. Quantitative real-time polymerase chain reaction (qRT-PCR) was executed to determine circ_0004277 and microRNA-134-5p (miR-134-5p) expression levels. The growth, migration and invasion of AML cells were tested by the cell counting kit-8 and Transwell experiment. Dual-luciferase reporter gene experiment, RNA immunoprecipitation (RIP) experiment and RNA pull-down experiment were executed to determine the targeting relationship between circ_0004277 and miR-134-5p. Western blot assay was used to detect single stranded DNA binding protein 2 (SSBP2) expression. We observed that circ_0004277 was down-regulated in AML, while miR-134-5p was up-regulated. Functionally, circ_0004277 overexpression or inhibition of miR-134-5p remarkably suppressed AML cell viability, migration and invasion. Furthermore, miR-134-5p served as a direct downstream target of circ_0004277 and SSBP2 was identified as a target of miR-134-5p. Compensation experiments showed that miR-134-5p mimics abolished the biological function of circ_0004277 on malignant phenotypes of AML cells. Collectively, circ_0004277 impedes AML development by adsorbing miR-134-5p and up-regulating SSBP2.

Citing Articles

Prognostic value of circular RNAs expression and their correlation with clinicopathological features in acute myeloid leukemia: a systematic review and meta-analysis.

Mirazimi Y, Aghayan A, Atashi A, Mohammadi D, Rafiee M Ann Hematol. 2025; .

PMID: 40087154 DOI: 10.1007/s00277-025-06300-6.


Prediction of circRNA-Disease Associations via Graph Isomorphism Transformer and Dual-Stream Neural Predictor.

Li H, Qian Y, Sun Z, Zhu H Biomolecules. 2025; 15(2).

PMID: 40001537 PMC: 11853643. DOI: 10.3390/biom15020234.


Identification of a Novel hsa_circ_0058058/miR-324-5p Axis and Prognostic/Predictive Molecules for Acute Myeloid Leukemia Outcome by Bioinformatics-Based Analysis.

Misir S, Yaman S, Petrovic N, Sami A, Akidan O, Hepokur C Biology (Basel). 2024; 13(7).

PMID: 39056681 PMC: 11273384. DOI: 10.3390/biology13070487.


CircRNAs as New Therapeutic Entities and Tools for Target Identification in Acute Myeloid Leukemia.

Nopora A, Weidle U Cancer Genomics Proteomics. 2024; 21(2):118-136.

PMID: 38423599 PMC: 10905271. DOI: 10.21873/cgp.20434.


New insight into circRNAs: characterization, strategies, and biomedical applications.

Feng X, Zhu S, Pu K, Huang H, Chen Y, Wang W Exp Hematol Oncol. 2023; 12(1):91.

PMID: 37828589 PMC: 10568798. DOI: 10.1186/s40164-023-00451-w.


References
1.
Chen C, Zhang L, Jiao Y, Zhou Y, Ge Q, Li P . miR-134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo. FEBS Lett. 2019; 593(10):1089-1101. DOI: 10.1002/1873-3468.13387. View

2.
Peng D, Wang H, Li L, Ma X, Chen Y, Zhou H . miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding. Leukemia. 2018; 32(5):1180-1188. DOI: 10.1038/s41375-018-0015-2. View

3.
Mah S, Buske C, Humphries R, Kuchenbauer F . miRNA*: a passenger stranded in RNA-induced silencing complex?. Crit Rev Eukaryot Gene Expr. 2010; 20(2):141-8. DOI: 10.1615/critreveukargeneexpr.v20.i2.40. View

4.
Zhang H, Jiang L, Sun D, Hou J, Ji Z . CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2017; 25(1):1-7. DOI: 10.1007/s12282-017-0793-9. View

5.
Zhou J, Zhou L, Tang X, Zhang J, Zhai L, Yi Y . Circ-Foxo3 is positively associated with the Foxo3 gene and leads to better prognosis of acute myeloid leukemia patients. BMC Cancer. 2019; 19(1):930. PMC: 6751826. DOI: 10.1186/s12885-019-5967-8. View